Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Opioid vaccine trial aims to block Drug's brain effects

NCT ID NCT04458545

First seen Apr 30, 2026 · Last updated Jun 16, 2026 · Updated 9 times

Summary

This study tests a vaccine that helps the body produce antibodies against oxycodone, a commonly abused prescription opioid. The goal is to reduce the drug's ability to reach the brain and lower its pleasurable effects. The trial involves 45 adults with opioid use disorder and focuses on safety, immune response, and drug liking. It is not a cure but a new tool to support ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Clinilabs Drug Development Corporation

    RECRUITING

    Eatontown, New Jersey, 07724, United States

    Contact Phone: •••-•••-••••

  • New York State Psychiatric Institute: Division on Substance Use Disorders

    ACTIVE_NOT_RECRUITING

    New York, New York, 10032, United States

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.